临床胰岛移植联盟中单纯胰岛移植与肾后胰岛移植治疗1型糖尿病的长期结局:CIT-08研究
CIT-08为前瞻性干预与观察性队列研究,纳入48例单纯胰岛移植和24例肾后胰岛移植的1型糖尿病伴低血糖感知受损成人,随访至8年。中位随访时移植物存活率分别为84%和69%,末次随访为56%和49%(P=0.007);两组严重低血糖无发生率均保持>90%。
要点
- 单纯胰岛移植与肾后胰岛移植中位随访移植物存活率分别为84%和69%(P=0.007)。
- 两组严重低血糖无发生率均保持>90%,多数受者达到HbA1c<7.0%的血糖目标。
- 74%的受者实现胰岛素不依赖,长期随访中超过半数维持胰岛素不依赖。
核心结论
- 胰岛移植可获得持久的移植物存活,使多数适应证的的低血糖感知受损受者在不发生严重低血糖的情况下达到血糖目标,单纯与肾后胰岛移植增加免疫抑制的安全性均可接受。
研究设计与样本
- 前瞻性干预与观察性队列研究,纳入单纯胰岛移植48例与肾后胰岛移植24例1型糖尿病伴低血糖感知受损成人。
- 在标准化免疫抑制下经门静脉输注一种或多种纯化人胰腺胰岛产品,随访至8年。
- 结局包括移植物存活(刺激后C肽≥0.3 ng/mL)、达标血糖控制(HbA1c<7.0%)、严重低血糖无发生与胰岛素不依赖。
主要发现
- 48例单纯胰岛移植与24例肾后胰岛移植受者中,分别有26例和8例带移植物功能完成长期随访,15例和7例带移植物功能退出随访,7例和9例发生移植物失功。
- 中位与末次随访时移植物存活率:单纯胰岛移植84%与56%,肾后胰岛移植69%与49%(P=0.007)。
- 维持移植后HbA1c<7.0%者:单纯胰岛移植77%与49%,肾后胰岛移植57%与35%(P=0.0017)。
- 两组严重低血糖无发生率均保持>90%;74%的单纯胰岛移植与肾后胰岛移植受者实现胰岛素不依赖,长期随访中超过半数维持胰岛素不依赖。
- 两组长期随访肾功能稳定,抗HLA致敏率低;严重不良事件发生率单纯胰岛移植为每患者年0.31,肾后胰岛移植为每患者年0.43。
关键数值与推荐
- 移植物存活定义为刺激后C肽≥0.3 ng/mL。
- 达标血糖控制定义为HbA1c<7.0%。
- 中位随访移植物存活率单纯胰岛移植84% vs 肾后胰岛移植69%(P=0.007);末次随访56% vs 49%。
- HbA1c<7.0%维持率中位随访单纯胰岛移植77% vs 肾后胰岛移植57%,末次随访49% vs 35%(P=0.0017)。
- 严重不良事件发生率单纯胰岛移植每患者年0.31 vs 肾后胰岛移植每患者年0.43。
临床怎么用
- 作者认为,对低血糖感知受损且适应证合适的受者,胰岛移植可带来持久移植物存活,使多数受者在不发生严重低血糖的情况下达到血糖目标。
- 作者认为单纯胰岛移植与肾后胰岛移植增加免疫抑制的安全性均可接受。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine long-term outcomes for islet-alone and islet-after-kidney transplantation in adults with type 1 diabetes complicated by impaired awareness of hypoglycemia. RESEARCH DESIGN AND METHODS: This was a prospective interventional and observational cohort study of islet-alone (n = 48) and islet-after-kidney (n = 24) transplant recipients followed for up to 8 years after intraportal infusion of one or more purified human pancreatic islet products under standardized immunosuppression. Outcomes included duration of islet graft survival (stimulated C-peptide ≥0.3 ng/mL), on-target glycemic control (HbA1c <7.0%), freedom from severe hypoglycemia, and insulin independence. RESULTS: Of the 48 islet-alone and 24 islet-after-kidney transplantation recipients, 26 and 8 completed long-term follow-up with islet graft function, 15 and 7 withdrew from follow-up with islet graft function, and 7 and 9 experienced islet graft failure, respectively. Actuarial islet graft survival at median and final follow-up was 84% and 56% for islet-alone and 69% and 49% for islet-after-kidney (P = 0.007) with 77% and 49% of islet-alone and 57% and 35% of islet-after-kidney transplantation recipients maintaining posttransplant HbA1c <7.0% (P = 0.0017); freedom from severe hypoglycemia was maintained at >90% in both cohorts. Insulin independence was achieved by 74% of islet-alone and islet-after-kidney transplantation recipients, with more than one-half maintaining insulin independence during long-term follow-up. Kidney function remained stable during long-term follow-up in both cohorts, and rates of sensitization against HLA were low. Severe adverse events occurred at 0.31 per patient-year for islet-alone and 0.43 per patient-year for islet-after-kidney transplantation. CONCLUSIONS: Islet transplantation results in durable islet graft survival permitting achievement of glycemic targets in the absence of severe hypoglycemia for most appropriately indicated recipients having impaired awareness of hypoglycemia, with acceptable safety of added immunosuppression for both islet-alone and islet-after-kidney transplantation.
引用
- Rickels MR, Eggerman TL, Bayman L, et al. Long-term Outcomes With Islet-Alone and Islet-After-Kidney Transplantation for Type 1 Diabetes in the Clinical Islet Transplantation Consortium: The CIT-08 Study. Diabetes Care. 2022. PMID: 36250905. doi:10.2337/dc21-2688
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。